Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01939496 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents
A Phase 4 study, sponsored by Janssen Scientific Affairs.
- Completed
- Registry status
- Phase 4
- Development phase
- 171
- Enrollment target
NCT01939496: Completed Phase 4 study, sponsored by Janssen Scientific Affairs.
NCT01939496 is a Phase 4 study that has completed, run by Janssen Scientific Affairs. The registered enrollment target is 171 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01939496, a Phase 4 study, has completed, sponsored by Janssen Scientific Affairs.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 171 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of canagliflozin (JNJ-28431754) on blood pressure reduction, compared to placebo, in patients with hypertension and type 2 diabetes mellitus and who are on stable doses of anti-hyperglycemic and anti-hypertensive agents. Overall safety and tolerability of canagliflozin will be assessed.
Primary Outcome
The blood pressure (BP) was evaluated by Ambulatory Blood Pressure Monitoring (ABPM) for all participants based on the 24-hour BP recordings.
Interventions
- DRUG Placebo
- DRUG Canagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2013-10 |
| Est. Completion | 2015-04 |
| Phase | Phase 4 |
What the finished NCT01939496 record still lists
NCT01939496 is an interventional study that assigns participants to a tested intervention. The registered 171 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01939496 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01939496 about?
NCT01939496 is a clinical study titled "Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents". The purpose of this study is to evaluate the effect of canagliflozin (JNJ-28431754) on blood pressure reduction, compared to placebo, in patients with hypertension and type 2 diabetes mellitus and who are on stable doses of anti-hyperglycemic and anti-hypertensive agents. Overall safety and tolerabi...
What is the current status of trial NCT01939496?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 171 participants. The study started on 2013-10. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01939496?
The interventions under investigation include: Placebo (DRUG), Canagliflozin (DRUG).
Who is sponsoring clinical trial NCT01939496?
This trial is sponsored by Janssen Scientific Affairs, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01939496's enrollment target sits among peer trials
171 484th of 2000 higher than 1,517 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02641145 · 171 participants · NA
Molecular Imaging of Primary Amyloid Cardiomyopathy
- NCT05541029 · 171 participants · NA
Music Listening: A Mechanistic Trial
- NCT05561127 · 171 participants · Phase 3
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel
- NCT05592938 · 171 participants · NA
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia